Cancer drug combo trial ends early – little known
Disease control
Terminated
This phase II trial tested a combination of two drugs, olinvacimab and pembrolizumab, in 19 women with metastatic triple-negative breast cancer. The goal was to see if the combination could shrink tumors. However, the study was terminated early, so we have limited information on …
Phase: PHASE2 • Sponsor: PharmAbcine • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC